-
Dr. Kelly Pekala is a highly skilled urologist with a specialization in open, robotic, and minimally invasive techniques. She has comprehensive training in genitourinary cancers, having completed her fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center, recognized as the top Urology program in the nation. Dr. Pekala employs a personalized approach to urologic care, treating a wide range of conditions and performing various procedures. In her free time, Dr. Pekala enjoys traveling, cooking, and swimming. She is dedicated to providing patient-centered care.
The services Dr. Pekala provides include:
- Management of prostate, bladder, and kidney cancers
- Treatment of benign prostatic hyperplasia
- Management of kidney stones and ureteropelvic junction obstruction
- Addressing erectile dysfunction and low testosterone
The procedures Dr. Pekala performs include:
- Cystectomy
- Prostatectomy
- Nephrectomy and partial nephrectomy
- Ureteroscopy
- Laser lithotripsy
- Transurethral resection of the prostate
- Prostate cancer focal therapy
- Ureteral reimplant
- Pyeloplasty
- Robotic and laparoscopic surgery
Languages: English, SpanishCertification: American Board of UrologyProfessional School: Vanderbilt University School of Medicine (Nashville, TN)Residency: University of Pittsburgh Medical Center (Pittsburgh, PA)Fellowship: Memorial Sloan Kettering Cancer Center (New York, NY)Medical Groups: MultiCare, MultiCare Medical PartnersResearch:Jiagge E, Jin DX, Newberg JY, Perea-Chamblee T, Pekala KR, Fong C, Waters M, Dei-Adomakoh Y, Erb G, Arora KS, Maund SL, Njiraini N, Ntekim A, Ma D, Thomas M, van Eeden R, Hegde P, Schultz N, Berger M, Frampton GM, Sokol ES, Carrot-Zhang J. Tumor Sequencing of African Ancestry reveals Differences in Clinically Relevant Somatic Alterations across Common Cancers. Cancer Cell (2023). PMID: 37890492.
Pekala KR, Shill DK, Austria MD, Langford A, Loeb S, Carlsson SV. Shared Decision Making Before Prostate Cancer Screening Decisions: A Review. Nature Reviews Urology (2024). PMID: 38168921.
Pekala KR, Bergengren O, Carlsson SV, Eastham JA. Active Surveillance should be considered for select men with ISUP Grade Group 2 prostate cancer. BMC Urology (2023). PMID: 37777716.
Bergengren O, Pekala KR, Matsoukas K, Feinberg J, Mungovan S, Bratt O, Bray F, Brawley O, Luckenbaugh A, Mucci L, Morgan T, Carlsson SV. 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A systematic review. European Urology (2023). PMID: 37202314.
